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Background: The presence of chronic kidney disease (CKD) in type 2 diabetes mellitus (T2DM) increases the risk of
cardiovascular disease (CVD) regardless of the presence of traditional cardiovascular risk factors. There is controversy
about the impact of each of the manifestations of CKD on the prevalence of CVD, whether it is greater with
decreased estimated glomerular filtration rate (eGFR) or increased urine albumin creatinine ratio (UACR).
Methods: This study is a national cross-sectional study performed in primary care consults. We selected participants of
both sexes who were aged 40 years or older, had been diagnosed with T2DM and had complete information on the
study variables recorded in their medical records. The participants were classified according to eGFR : ≥ 60; 45–59; 30–44;
<30 mL/min/1.73 m2 and UACR : < 30; 30–299; ≥300 mg/gr. The results were adjusted to compare the prevalence of
CVD across all categories.
Results: A total of 1141 participants were included. Compared to participants with eGFR > 60 mL/min/1.73 m2
those with eGFR between 30–44 mL/min/m2, (OR = 2.3; 95% CI, 1.4-3.9); and eGFR < 30 mL/min/1.73 m2 (OR = 4.1
95% CI 1.6-10.2) showed increased likelihood of having CVD. Participants with UACR ≥ 30 mg/g compared to
participants with UACR < 30 mg/g increased significantly the likelihood of having CVD, especially with UACR
above 300 mg/g, (OR = 1.6; 95% CI 1.1-2.4 for UACR = 30–299 mg/g; OR = 3.9; CI 1.6-9.5 for UACR ≥ 300 mg/g).
Conclusion: The decrease in eGFR and increase in UACR are independent risk factors that increase the prevalence of
CVD in participants with T2DM and these factors are independent of each other and of other known cardiovascular risk
factors. In our study the impact of mild decreased eGFR in T2DM on CVD was lower than the impact of increased
UACR. It is necessary to determine not only UACR but also eGFR for all patients with T2DM, both at the time of
diagnosis and during follow-up, to identify those patients at high risk of cardiovascular complications.
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Chronic kidney disease (CKD) is a serious public health
problem that increases the risk of overall mortality, car-
diovascular disease (CVD), and progression to end-stage
renal disease regardless of the presence of traditional
cardiovascular risk factors [1-3].
The presence of microalbuminuria in diabetes mellitus
has been considered one of the first clinical signs of* Correspondence: gabriel.coll@ias.scs.es
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article, unless otherwise stated.diabetic nephropathy. Microalbuminuria can progress to
macroalbuminuria, subsequently leading to a decrease in
the estimated glomerular filtration rate (eGFR), and finally
to end-stage renal disease [4]. This process was originally
described for type 1 diabetes and may be different in pa-
tients with type 2 diabetes mellitus (T2DM).
Controversy exists regarding the impact of each of the
manifestations of CKD on the prevalence of CVD, whether
it would be greater with increased urine albumin creatinine
ratio (UACR) or a decreased eGFR. Several epidemiological
studies show that increased UACR is associated with a
higher prevalence of CVD; this association is observedMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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UACR influences the clinical outcome [5,6], particularly re-
garding cardiovascular complications [7,8]. It has been
found that people with decreased eGFR and normal UACR
have a lower CVD risk than individuals with increased
UACR and normal eGFR [7,9,10]. In some studies in pa-
tients with T2DM, it has been observed that increased
UACR and decreased eGFR are associated with the same
prevalence of CVD, although the increase in UACR seems
to relate more strongly to cardiovascular death [11,12].
Most clinical practice guidelines advise determining
not only UACR but also eGFR, as decreased eGFR with
normal UACR is common in T2DM [13-15]. The de-
crease in eGFR and increase in UACR are independently
associated with increased overall mortality [11] and high
prevalence of CVD [16,17], which are even higher if they
are both present.
This study was designed to determine the relationship
of the decrease in eGFR and the increase in UACR with
the prevalence of CVD in participants with T2DM being
treated in primary care settings in Spain.
Methods
Study design and population
A detailed description of the methodology used has been
described previously [18]. This study was a national cross-
sectional study performed in primary care consults. The
participants included both genders and were over 40 years
old. Moreover, the participants were diagnosed with
TDM2, and they had all of the variables necessary for the
study included in their clinical history. Each researcher in-
cluded 15 participants who met the inclusion criteria, a
maximum of 3 participants per day. The participants were
selected by convenience sample of the first 3 patients with
diabetes each day who came to the consult for any reason
and met the inclusion criteria until complete the number
of participants per researcher.
The information for each participant was collected in
the period from February to July 2011. The Ethical and
Clinical Investigation Committee of the Institut d’ Assis-
tència Sanitària (IAS) in Salt, Girona, Spain approved
the study. To obtain the necessary data for this study
from the clinical history of participants, all participants
provided written informed consent.
Variables and procedure
We followed a study protocol to ensure correct collec-
tion of variables. The following variables were collected
during the visit: age, gender, ethnicity, weight, height,
body mass index (BMI) was calculated as weight in kilo-
grams divided in meters squared; obesity was defined as
BMI ≥ 30 kg/m2, abdominal waist circumference, cardio-
vascular risk factors. Cardiovascular diseases was col-
lected through the medical record as a history of stroke(ischaemic cerebrovascular disease) included only
symptomatic brain infarction, and did not include silent
brain infarction, transient ischaemic attack or brain
haemorrhage. Coronary heart disease included a previ-
ous history of myocardial infarction, angina pectoris,
the presence of coronary interventions or the presence
of ECG abnormalities suggestive of coronary heart dis-
ease. Peripheral arterial disease was diagnosed by an
ankle-brachial pressure index of < 0.9 and/or two absent
foot pulses. Diabetes mellitus was defined as fasting
glucose ≥ 126 mg/dL or non-fasting glucose ≥ 200 mg/
dL or use of glucose-lowering drugs. Hypertension was
defined as systolic blood pressure of 140 mmHg or
greater, diastolic blood pressure of 90 mmHg or greater,
or use of antihypertensive medications irrespective of
blood pressure. Hyperlipidemia was defined as total
cholesterol ≥ 250 mg/dL, LDL cholesterol > 155 mg/dL,
HDL cholesterol < 40 mg/dL in men and < 48 mg/dL in
women, triglycerides > 150 mg/dL or pharmacologic
lipid lowering treatment. Cigarette smoking was de-
fined as:never/past/current.
The following clinical and analytical measurements
were collected: DM2 duration, arterial pressure (average
of the last three determinations), drugs taken by the pa-
tient at the time the data were collected (antidiabetic,
antihypertensives, hypolipemiant, antiplatelet, and anti-
coagulants). Basal glycaemia, glycosylated haemoglobin
(HbA1c), haemoglobin, total cholesterol, LDL choles-
terol, HDL cholesterol, non-HDL cholesterol, triglycer-
ides, serum creatinine after overnight fasting for at least
12 hr, and the UACR in a urine sample collected in the
first morning urine specimen, using the most recent
value of the last 12 months.
In this study, the presence of CKD was based on
KDOQI criteria as follows: patients with eGFR < 60 mL/
min/1.73 m2 or the presence of renal damage if UACR
values were elevated (UACR ≥ 30 mg/g). CKD- EPI equa-
tion was used to calculate the eGFR [19]. Albuminuria
was defined as a UACR of 30 mg/g or more. Microalbumi-
nuria was defined as a UACR ranging from 30 to 299 mg/g,
and macroalbuminuria was defined as a UACR of 300 mg/
g or more. Two determinations of eGFR and UACR, in a
period of three or more months, must be made. The cases
that did not fulfil two determinations were excluded from
the final analysis of the study.
The participants were classified according to simplified
Kidney Disease Improvement Global Outcomes (KDIGO
2012) Guidelines [20], eGFR : ≥ 60; 45–59; 30–44;
<30 mL/min/1.73 m2 and UACR : < 30; 30–299;
≥300 mg/gr.
To compare the prevalence of CVD across all categories,
the results were adjusted by age and sex (Model 1); by age,
sex, hypertension, dyslipidaemia, smoking, and BMI
(Model 2); and by age, sex, hypertension, dyslipidaemia,
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Normal eGFR values were considered to be equal to or
higher than 60 mL/min/1.73 m2; decreased eGFR values
were less than 60 mL/min/1.73 m2; normal UACR values
were below 30 mg/g; and increased UACR values were
above 30 mg/g.Statistical analysis
Measurements of central tendency and dispersion were
used to perform a descriptive analysis of the quantitative
variables studied. Absolute and relative frequencies were
used for qualitative variables. The patient groups were
established according to the UACR and eGFR values. The
differences in demographic and clinical characteristics be-
tween groups were calculated by comparison of means in
quantitative variables, parametric or nonparametric ac-
cording to the normal distribution of each variable, and
contingency tables for qualitative variables, with a Yates
correction when necessary. The prevalence of CVD was
established for each of the eGFR and UACR categories.
To determine the variables associated with CVD in each
category, different logistic regression models were ad-
justed to control for potential confounders. We performed
also a multivariate analysis considering the eGFR andTable 1 Clinical and metabolic characteristics of participants
Variables ALL
n 1141
Age (years); mean (SD) 66.8 (11.3)
Gender (men) ,% 60.6
Duration diabetes (years), mean (SD) 9.1 (6.7)
Body mass index (kg/m2) mean (SD) 30.3 (5.2)
Abdominal waist circumference (cm); mean (SD) 100.0 (17.1)
Obesity (%) 46.5
HbA1c; mean (SD) 7.3 (1.3)
Smoking (%) 13.8
Hyperlipidemia (%) 67,9
Hypertension (%) 75.1
Systolic Blood Pressure (mmHg); mean (SD) 134.5 (13.2)
Diastolic Blood Pressure (mmHg); mean (SD) 77.0 (9.1)
Cholesterol total (mmol/L); mean (SD) 4.70 (0.93)
Cholesterol HDL (mmol/L); mean (SD) 1.29 (0.35)
Cholesterol LDL (mmol/L); mean (SD) 2.79 (0.83)
Cholesterol non HDL (mmol/L); mean (SD) 3.49 (0.91)
Tryglicerides (mmol/L); mean (SD) 1.69 (0.96)
Plasmatic creatinina (mg/dl); mean (SD) 0.93 (0.3)
Glomerular filtration ratio mL/min/1,73 m2; mean (SD) 79.9 (23.5)
Urine albumin-creatinine ratio (mg/g); mean (SD) 39.2 (144.3)
eGFR: estimated glomerular filtration rate according to CKD-EPI in mL/min/1.73 m2;UACR as continuous variables from point considered
normal.
The results were expressed as absolute numbers, per-
centages, medians, standard deviations, odds ratios
(ORs), and 95% CI. The statistical significance was set at
0.05 when contrasting hypotheses. The data analysis and
processing were performed using the SPSS 17.0 statis-
tical program for Windows.
Results
During the recruitment, 1279 participants were included
in the study, but 138 (10.8%) participants were excluded
because of incomplete or erroneous data. To rule out bias
attributable to participants excluded from the study, we
compared the two groups and we found no significant dif-
ferences. The final sample size was 1141 participants.
Table 1 shows clinical and metabolic characteristics of
the 1141 participants. Participants with GFR < 60 mL/
min/m2 compared to participants with GFR ≥ 60 mL/min/
m2 were more frequently older, had longer diabetes dur-
ation and had a higher rate of hypertension. When com-
paring participants with UACR ≥ 30 mg/g and participants
with UACR <30 mg/g, those had longer diabetes duration,
higher systolic blood pressure, triglycerides, higher rate of
hypertension and lower eGFR.with type 2 diabetes (n = 1,141)
eGFR ≥60 eGFR <60 UACR < 30 UACR ≥ 30
761 380 987 154
63.8 (10.9) 72.7 (9.4) 66.4 (11.2) 68.7 (11.1)
80.3 50.7 60.7 59.7
8.4 (6.5) 10.2 (6.9) 8.8 (6.5) 10.4 (7.4)
30.6 (5.4) 29.5 (4.8) 30.1 (5.2) 31.1 (5.5)
99.9 (16.9) 99.9 (18.0) 99.5 (17.3) 101.8 (16.9)
48.9 41.3 45.9 49.4
7.6 (1.4) 7.2 (1.2) 7.2 (1.3) 7.7 (1.4)
39.4 50.5 42.5 47.4
67.1 68.9 67.5 69.5
70.0 83.2 72.9 83.8
134.4 (13.0) 134.8 (13.5) 134.1 (12.7) 137.4 (15.5)
78.1 (8.7) 74.7 (9.4) 77.1 (9.0) 76.7 (9.7)
187.1 (37.3) 176.8 (36.1) 183.8 (36.8) 183.3 (40.3)
49.1 (13.1) 45.8 (13.8) 48.3 (13.4) 46.0 (12.5)
110.4 (31.9) 103.1 (31.9) 108.4 (31.8) 105.0 (33.6)
137.9 (36.2) 131.2 (35.1) 135.4 (35.4) 137.5 (39.4)
149.8 (91.2) 154.4 (94.2) 146.5 (83.7) 182.3 (130.7)
0.78 (0.13) 1.2 (0.3) 0.9 (0.3) 1.0 (0.4)
89.6 (19.7) 47.6 (9.6) 76.8 (25.7) 68.3 (27.7)
17.2 (35.2) 28.3 (52.7) 7.5 (6.2) 107 (66.2)
UACR: urinary albumin creatinin rate in mg/gr.
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pants classified by GFR and UACR according to adapted
KDIGO Guidelines [20].
Table 3 shows the characteristics of participants accord-
ing to the different combinations of UACR and eGFR. Par-
ticipants with decreased eGFR were older; they had a
higher prevalence of hypertension, and a higher percent-
age of them were receiving antihypertensive treatment.
These participants had less peripheral arterial disease and
higher prevalences of coronary heart disease and stroke.
In the group of participants with increased UACR, we ob-
served higher levels of HbA1c and a greater number of
participants being treated with insulin. No interactions be-
tween eGFR and albumiburia were observed.
Table 4 and Figure 1 shows the results for the preva-
lence of CVD based on the unadjusted model and
after adjusting the results according to Models 1, 2
and 3. Compared to participants with GFR ≥ 60 mL/
min/m2 those with GFR < 60 mL/min/m2 (Model 3)
increased significantly the likelihood of having CVD,
especially with eGFR less than 45 mL/min/m2, (OR =
1,2; 95% CI 0.9-1.8 for eGFR 45–59 mL/min/m2; OR =
2.3; CI 1.4-3.9 for eGFR 30–44 mL/min/m2 and OR = 4.1;
CI 1.6-10.2 for eGFR < 30 mL/min/m2). Compared to par-
ticipants with UACR < 30 mg/g those with UACR ≥
30 mg/g (Model 3) increased significantly the likelihood
of having CVD, especially with UACR above 300 mg/g,
(OR = 1.6; 95% CI 1.1-2.4 for UACR = 30–299 mg/g;
OR = 3.9; CI 1.6-9.5 for UACR ≥ 300 mg/g). Both, de-
creased eGFR and increased UACR, had higher likeli-
hood of having CVD.
Discussion
In this study, we observed that in participants with T2DM
treated in primary care settings, decreased eGFR and in-
creased UACR were associated with a higher rate of cardio-
vascular disease. The results of our study show a higher
prevalence of CVD (30.9% vs. 8.5%) than in the study by
Yokoyama et al. [17] The older age of the participants (67
vs. 58 years), higher BMI (30 vs. 24 kg/m2), differences in
systolic blood pressure (135 vs. 128 mmHg) and diastolic
blood pressure (77 vs. 75 mmHg), and increased waist cir-
cumference could explain these differences.Table 2 Distribution of chronic kidney disease markers by KD
eGFR UACR <10 mg/gr UACR 10-2
>90 246 (34.0) 90 (3
60-90 255 (35.3) 85 (3
45-60 46 (6.4) 20 (7
30-45 164 (22.7) 62 (2
<30 12 (1.7) 7 (2
TOTAL 723 264
KDIGO: Kidney Disease Improvement Global Outcome.The increase in UACR relates to the presence of renal
disease and CVD [21] and indicates the probable exist-
ence of generalised endothelial damage [22]. An associ-
ation has been established between increased UACR
levels and increased coronary risk [23] and stroke [24].
In Brantsma et al. [7] study, the increase in UACR was a
better predictor for the development of CVD than the
decrease in eGFR; subjects with moderately decreased
eGFR and normal UACR had no increased risk of CVD,
whereas participants with moderately decreased eGFR
and increased UACR had an increased risk of CVD. Not-
ably, the number of subjects with eGFR < 45 mL/min/
1.73 m2 was very small, and the significance of eGFR on
CVD risk could have been underestimated. When com-
paring the risk of cardiovascular and all cause mortality
by assessing different degrees of eGFR and UACR, for
participants with increased UACR and eGFR greater
than 60 mL/min/1.73 m2,the initial stages of CKD, it
was found that the risk of CVD was higher in partici-
pants with macroalbuminuria than in participants with
microalbuminuria. Decreased eGFR in these stages was
not associated with an increased CVD risk. However,
CVD risk increases progressively with decreasing eGFR
below 60 mL/min/1.73 m2.
Association between a moderate decreased eGFR and
increased CVD risk has been observed in some epi-
demiological studies [1,25,26]; however, this relationship
is not present, or is very weak, in other studies [27,28].
Go et al. [29] showed a gradual association between re-
duced eGFR and increased risk of CVD death and hospi-
talisation, regardless of other known risk factors, history
of CVD, and the presence of proteinuria. This risk was
evident when eGFR was less than 60 mL/min/1.73 m2
and increased significantly for subjects whose eGFR was
less than 45 mL/min/1.73 m2 [11].
The clinical factors associated with decreased eGFR and
increased UACR may be common, but could also be differ-
ent. The decrease in eGFR and increase in UACR are risk
factors for developing CVD; it is unknown whether this as-
sociation is independent of the presence of other known
cardiovascular risk factors. It has been suggested that the
increase in UACR and decrease in eGFR might be renal
manifestations of endothelial dysfunction and systemicIGO criteria
9 mg/gr UACR ≥ 30 mg/gr Total
4.1) 40 (26.0) 376
2.2) 45 (29.2) 385
.6) 26 (16.9) 92
3.5) 36 (23.4) 262
.7) 7 (4.5) 23
154 1141
Table 3 Patient characteristics according to the glomerular filtration rate and urinary albumin creatinine ratio
Variables Values eGFR
(nm)/
eGFR
(nm)/
eGFR ↓/ eGFR ↓/ P value UACR↑
vs
P value eGFR ↓
vs
UACR(nm) UACR ↑ UACR
(nm)
UACR ↑ UACR(nm) eGFR (nm)
N 1141 674 85 311 69 154 vs 987 380 vs 761
Age (years) (SD) 66.8 (11.3) 63.7 (11.0) 64.3 (10.2) 72.4 (9.3) 74.1 (9.7) 0.048 <0.001
Gender (men,%) 691 (60.6) 345 (51.0) 44 (48.2) 254 (81.7) 51 (73.9) 0.823 <0.001
T2DM Duration (years) (SD) 9.1 (6.7) 8.4 (6.4) 8.7 (6.3) 9.6 (6.5) 12.6 (8.1) 0.007 <0.001
BMI (kg/m2) (SD) 30.3 (5.2) 30.5 (5.4) 31.2 (5.4) 29.3 (4.5) 30.9 (5.6) 0.058 0.004
BMI ≥30 kg/m2 (%) 529 (46.4) 327 (48.4) 45 (52.9) 126 (40.5) 31 (44.9) 0.424 0.016
Waist circumference (cm) (SD) 100.0
(17.1)
99.8 (16.8) 100.4 (17.5) 99.0 (18.3) 103.6 (16.1) 0.118 0.514
HbA1c mean (SD) 7.3 (1.3) 7.3 (1.3) 7.8 (1.5) 7.1 (1.2) 7.5 (1.1) <0.001 0.052
Smoking n (%) 0.467 <0.001
Current 158 (13.8) 96 (14.2) 18 (21.2) 37 (11.9) 7 (10.1)
Past-smoker 334 (29.3) 164 (24.3) 22 (25.9) 122 (39.2) 26 (37.7)
Never 649 (56.9) 416 (61.5) 45 (52.9) 152 (48.9) 36 (52.2)
Insulin n (%) 281 (24.6) 159 (23.5) 26 (30.6) 65 (20.9) 31 (44.9) <0.001 0.725
Oral antidiabetic agents n (%) 965 (84.6) 586 (86.7) 77 (90.6) 249 (80.1) 53 (76.8) 0.953 0.001
Oral antidiabetic agents + insulin n (%) 210 (18.4) 124 (18.3) 23 (27.1) 43 (13.8) 20 (29.0) 0.001 0.261
Hyperlipidemia n (%) 773 (67.7) 228 (33.7) 22 (25.9) 93 (29.9) 25 (36.2) 0.621 0.540
Hypertension n (%) 849 (74.4) 465 (68.8) 68 (80.0) 255 (82.0) 61 (88.4) 0.004 <0.001
Antihypertensive treatment n (%) 866 (75.9) 466 (68.9) 74 (87.1) 263 (84.6) 63 (91.3) <0.001 <0.001
Systolic Blood Pressure (mmHg) (SD) 134.5
(13.2)
134.0
(35.4)
137.8 (14.9) 134.4
(12.8)
136.9 (16.4) 0.018 0.539
Diastolic Blood Pressure (mmHg) (SD) 77.0 (9.1) 78.1 (8.8) 78.2 (9.3) 74.7 (9.2) 74.8 (9.8) 0.892 <0.001
Cholesterol total (mmol/L) (SD) 183.7
(37.2)
186.9
(36.8)
189.1 (41.4) 177.0
(35.8)
176.2 (37.9) 0.853 <0.001
Cholesterol HDL (mmol/L) (SD) 135.7
(35.9)
137.4
(35.4)
142.8 (41.4) 131.2
(35.0)
131.0 (35.9) 0.514 0.004
Cholesterol LDL (mmol/L) (SD) 107.9
(32.1)
110.5
(35.4)
109.2 (33.5) 103.8
(31.6)
99.6 (33.2) 0.211 <0.001
Cholesterol non HDL (mmol/L) (SD) 48.0 (13.5) 49.5 (13.3) 46.2 (11.5) 45.8 (13.8) 45.7 (13.7) 0.055 <0.001
Tryglicerides (mmol/L) (SD) 151.3
(92.2)
146.4
(88.8)
177.3
(105.4)
146.8
(71.6)
188.4
(157.0)
<0.001 0.296
Lipid-lowering therapy n, (%) 738 (64.7) 413 (61.1) 60 (70.6) 215 (69.1) 50 (72.5) 0.060 0.012
Plasmatic creatinina (mg/dl) (SD) 0.92 (0.3) 0.78 (0.13) 0.78 (0.14) 1.17 (0.23) 1.31 (0.45) <0.001 <0.001
Glomerular filtration ratio, mL/min/1,73 m2
(SD)
75.6 (26.1) 89.8 (19.7) 88.3 (19.9) 48.5 (9.1) 43.6 (10.6) <0.001 <0.001
Urine albumin-creatinine ratio (mg/g) (SD) 20,9 (42,2) 7.2 (5.9) 96.7 (61.3) 8.0 (6.7) 119.8 (70.1) <0.001 0.002
Coronary heart disease (%) 163 (14.3) 67 (9.9) 9 (10.6) 68 (21.9) 19 (27.5) 0,137 <0.001
Peripheral arterial disease (%) 91 (8.0) 32 (4.7) 8 (9.4) 33 (10.6) 18 (26.1) <0.001 <0.001
Stroke (%) 72 (6.3) 31 (4.6) 5 (5.9) 29 (9.3) 7 (10.1) 0.416 0.002
p-value bettween interactions low eGFR and albuminuria,> 0.05 in all cases.
nm: normal; eGFR: estimated glomerular filtration rate according to CKD-EPI in mL/min/1.73 m2; UACR: urinary albumin creatinin rate in mg/gr; BMI: body
mass index.
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UACR and decreased eGFR could be markers of different
pathological processes [30].Cardiovascular and renal complications share common
risk factors, such as hypertension, hyperlipidaemia, obes-
ity, hyperglycaemia, left ventricular hypertrophy, increased
Table 4 Multivariate analysis of chronic kidney disease impact on the prevalence of cardiovascular disease
Unadjusted model (OR; CI95%) Model 1 (OR; CI95%) Model 2 (OR; CI95%) Model 3 (OR; CI95%)
Glomerular filtration rate (eGFR)
eGFR ≥ 60 mL/min/1.73 m2 1 1 1 1
eGFR 45–59 mL/min/1.73 m2 2.07 (1.5-2.8) 1.2 (0.9-1.7) 1.2 (0.9-1.8) 1.2 (0.9-1.8)
eGFR 30–44 mL/min/1.73 m2 4.6 (2.9-7.3) 2.5 (1.5-4.1) 2.3 (1.4-3.8) 2.3 (1.4-3.9)
eGFR < 30 mL/min/1.73 m2 8.4 (3.6-19.9) 4.3 (1.7-10.7) 4.1 (1.6-10.2) 4.1 (1.6-10.2)
For each unit below 60 mL/min/1.73 m2 1.072 (1.06-1.09) 1.045 (1.03-1.06) 1.042 (1.02-1.06) 1.043 (1.02-1.06)
UACR
Normoalbuminuria 1 1 1 1
Microlbuminuria (30–299 mg/gr) 1.9 (1.4-2.7) 1.8 (1.2-2.6) 1.8 (1.3-2.7) 1.6 (1.1-2.4)
Macroalbuminuria (≥300 mg/gr) 5.0 (2.3-11.1) 4.6 (1.9-10.9) 4.2 (1.8-10.2) 3.9 (1.6 -9.5)
For each unit above 29 mg/gr 1.001 (0.99-1.01) 1.001 (0.99-1.01) 1.001 (0.99-1.01) 1.001 (0.99-1.01)
UACR (normal) + GFR (normal) 1 1 1 1
UACR ↑ and eGFR ↓ 3.3 (1.5-7.3) 2.3 (1.0-5.3) 2.4 (1.0-5.4) 2.2 (0.9-5.2)
GFR: estimated glomerular filtration rate. eGFR (normal): ≥ 60 mL/min/1,73 m2. eGFR↓: < 60 mL/min/1,73 m2.
UACR: Urine albumin/creatinine ratio . UACR (normal) < 30 mg/g. UACR ↑: ≥ 30 mg/g.
Normoalbuminuria: UACR < 30 mg/g. Microalbuminuria: UACR = 30–299 mg/g . Macroalbuminuria: UACR >300 mg/g.
Model 1 Adjusted for age and sex.
Model 2 Adjusted for age, sex, hypertension, dislipidaemia, tobacco and Body Mass Index.
Model 3 Adjusted for age, sex, hypertension, dislipidaemia , tobacco, Body Mass Index , HbA1c and T2DM duration.
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http://www.biomedcentral.com/1471-2369/15/150inflammatory markers, increased vascular permeability,
and disorders of the coagulation system and fibrinolysis
[1,29-32]. The existence of CKD may indicate that these
risk factors have been present for a long period of time,
causing a greater or lesser prevalence of CVD related to
their duration.
According to other studies [12,33], we observed a low
prevalence of CVD in our participants with mild de-
creased eGFR although the relationship between eGFR
as a continuous variable and the prevalence of CVD is
strong. In contrast to the study by Solini et al. [34], we
did not observe a significant increase in the prevalence
of CVD in the group with decreased eGFR and increasedFigure 1 Odds ratio of cardiovascular disease in Type 2 Diabetes MelUACR, most likely because of the small number of par-
ticipants who had this combination in our study, which
determined that the results of this group are most likely
not relevant. Another possibility is that in this group of
participants , most have an eGFR and UACR in closer to
normal areas, with lower cardiovascular risk.
Our study showed different results from those of the
meta-analysis by Lee et al. [24]; the group of participants
with decreased eGFR had a higher prevalence of stroke
than the group with increased UACR. Both markers of
renal dysfunction, decreased eGFR and increased UACR,
are associated with a higher prevalence of CVD in dia-
betic patients; the presence of one or both markers oflitus according to eGFR and UACR.
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http://www.biomedcentral.com/1471-2369/15/150renal dysfunction would indicate the presence of a vas-
cular disorder, and the presence of CVD itself causes a
deterioration of renal function [35,36]. In this study, the
OR of developing CVD increased significantly below
eGFR 45 mL/min/1.73 m2 and particularly with levels
below 30 mL/min/1.73 m2.
Among the study’s limitations, it should be men-
tioned that it is a cross-sectional study; therefore, a
causal relationship cannot be established. Although the
study variables were collected from the medical records
of participants by the researcher, the possibility of clin-
ical underdiagnosis cannot be ruled out. Only a small
number of participants had UACR ≥ 300 mg/ and/or
eGFR < 30 mL/min/1.73 m2, which limits the ability of
the study to assess the impact of eGFR and UACR in
the most advanced stages of CKD. The generalisation
of our findings may be limited; all the participants in
this study had T2DM and were willing to participate
voluntarily in the study. However, we believe that this
population is representative of the type of care that is
performed in primary care settings. Finally, the serum
creatinine level and UACR were not measured cen-
trally, which may affect the accuracy of the results.
Among the strengths of the study, it should be noted
that this is a national study with a large sample of pa-
tients with T2DM, in which family physicians were
heavily involved in the management of the disease; and
at least 2 of 3 measurements had to be altered over a
period of at least 3 months to establish the diagnosis of
chronic kidney disease.
Conclusion
The decrease in eGFR and increase in UACR are inde-
pendent risk factors that increase the prevalence of CVD
in patients with T2DM. In our study the impact of mild
decreased GFR in T2DM on CVD was lower than the
impact of increased UACR. These results suggest that it
is necessary to determine both had higher likelihood of
having CVD and UACR for all patients with T2DM—at
the time of diagnosis and during follow-up—to identify
patients at high risk of cardiovascular complications, to
establish the proper preventive measures, and to inten-
sify control in patients with T2DM and CKD, in an effort
to reduce cardiovascular morbidity and mortality.
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